angiotensin-converting enzyme inhibitors

PreclinicalSmall molecule

angiotensin-converting enzyme inhibitors is one of 177 small molecule programs targeting Mitral regurgitation. It is currently in Preclinical.

Indications

Total Trials

Active Trials

176

Competitors

Pipeline

Status by Indication[3][1]

Indication

Mitral RegurgitationActive, not recruiting

Skin CancerActive, not recruiting

PneumoniaActive, not recruiting

SepsisActive, not recruiting

HypertensionActive, not recruiting

Chronic Kidney DiseaseActive, not recruiting

Mitral RegurgitationPreclinical

Active, not recruiting

Skin CancerPreclinical

Active, not recruiting

PneumoniaPreclinical

Active, not recruiting

SepsisPreclinical

Active, not recruiting

HypertensionPreclinical

Active, not recruiting

Chronic Kidney DiseasePreclinical

Active, not recruiting

Competition

Competitive Landscape

169 competitors in Chronic Kidney Disease

#DrugCompanyPhaseTrials

Uloric

Takeda

Preclinical

2 2

Sovaldi

Gilead

Preclinical

1 3

Glucotrol

Pfizer

Preclinical

1 4

Vemlidy

Gilead

Preclinical

1 5

Lorelco

Sanofi

Preclinical

1 6

Activase

Flomax

Verquvo

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 9

PROCRIT

WWim Janssens

Preclinical

1 10

Januvia

ZZydus Therapeutics Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Pneumonia1 trial

Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study

Not yet recruiting·—··NCT07262710·13,656 enrolled

Hypertension1 trial

Effect of Caldine® on Renal Function in Balanced Hypertension

Terminated· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT02240641·5,417 enrolled

Mitral regurgitation1 trial

Impact of Medical and Surgical Therapy on Functional Mitral Regurgitation

Completed·—·N/A·NCT00224809·250 enrolled

Brain Infarction1 trial

Angiotensin II Receptor Blockers (ARB) and ACE Inhibitors (ACEI) on Silent Brain Infarction and Cognitive Decline

Completed·NNara Medical University·Phase 4·NCT00126516·395 enrolled

Chronic Kidney Disease1 trial

Pentoxifylline on Inflammatory Markers in Non-Diabetic Chronic Kidney Disease Patients

Completed·—·N/A·NCT07315139·42 enrolled

3 more indications

Sepsis1 trial

Antihypertensive Medications and the Risk of Sepsis

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT02248896·1,129,062 enrolled

Skin Cancer1 trial

Hydrochlorothiazide and Risk of Skin Cancer

Completed·CCanadian Network for Observational Drug Effect Studies, CNODES··NCT04334824·2,953,748 enrolled

Prevention1 trial

Prevention of Events With Angiotensin-Converting Enzyme Inhibitor Therapy (PEACE)

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 3·NCT00000558

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for angiotensin-converting enzyme inhibitors. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — angiotensin-converting enzyme inhibitors compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for angiotensin-converting enzyme inhibitors. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Boehringer Ingelheim company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Boehringer Ingelheim

angiotensin-converting enzyme inhibitors

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Pneumonia1 trial

Hypertension1 trial

Mitral regurgitation1 trial

Brain Infarction1 trial

Chronic Kidney Disease1 trial

Sepsis1 trial

Skin Cancer1 trial

Prevention1 trial

References

Drug Info

Quick Facts

Related News